Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New insights into progenitor exhausted T cell populations.

Nature reviews. Immunology·2026
Same author

LEF1 and niche factors determine T cell stemness across chronic diseases.

Cell·2026
Same author

Intense Myocardial Uptake in a Patient with Fabry Disease - a new cause of false positive of Bone Scintigraphy mimicking cardiac amyloidosis.

European heart journal. Cardiovascular Imaging·2026
Same author

TOX drives CD4<sup>+</sup> T<sub>H</sub>1 effector function, antitumor immunity and autoimmune pathology.

Nature immunology·2026
Same author

Effect of mavacamten on left ventricular diastolic function and left atrial remodelling in obstructive hypertrophic cardiomyopathy.

Archives of cardiovascular diseases·2026
Same author

Fixing the heart but losing the patient: the moral architecture of drug use-associated endocarditis.

Heart (British Cardiac Society)·2026
Same journal

Myeloid cells as sources and targets of IL-1 family cytokines in cancer.

Seminars in immunology·2026
Same journal

Interleukin-1-mediated inflammatory memory: Protective training or maladaptive tumor imprinting?

Seminars in immunology·2026
Same journal

Chronic stress at the crossroads: Decoding the HPA-SAM-immune-gut axis in inflammatory bowel disease pathogenesis and therapeutics.

Seminars in immunology·2026
Same journal

Protein tyrosine kinases in dendritic cell-mediated anti-cancer immunity.

Seminars in immunology·2026
Same journal

The immune system in Latin America and the Caribbean: Insights into diseases and diversity from local perspectives.

Seminars in immunology·2026
Same journal

Introduction to the special issue: T<sub>H</sub>9 cells in diseases.

Seminars in immunology·2026
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Specificity in cancer immunotherapy.

Andrea Schietinger1, Mary Philip, Hans Schreiber

  • 1Department of Pathology and Committee on Immunology, The University of Chicago, 5841 South Maryland Avenue MC 3008, Chicago, IL 60637, USA. hszz@midway.uchicago.edu

Seminars in Immunology
|August 8, 2008
PubMed
Summary
This summary is machine-generated.

Cancer cells have unique antigens caused by mutations that the immune system can target. Current immunotherapies use tumor-associated antigens instead of these ideal tumor-specific antigens, limiting effectiveness.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

Related Experiment Videos

Last Updated: Jul 3, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

Area of Science:

  • Tumor Immunology
  • Cancer Immunotherapy

Background:

  • Tumor immunology research has long sought to understand cancer cell antigens and immune recognition.
  • Truly tumor-specific antigens, arising from somatic mutations, are known to exist and can elicit immune responses.

Purpose of the Study:

  • To review the identification, immunological relevance, and clinical application of tumor-specific antigens.
  • To explore reasons why tumor-specific antigens are not currently the primary targets in cancer immunotherapy.
  • To propose novel strategies for enhancing cancer immunotherapy, particularly for solid tumors.

Main Methods:

  • Review of existing literature on tumor immunology and cancer immunotherapy.
  • Analysis of the characteristics and potential of tumor-specific antigens.
  • Discussion of current therapeutic targets versus ideal targets in immunotherapy.

Main Results:

  • Tumor-specific antigens are exclusively expressed by cancer cells and are crucial for tumorigenicity.
  • Current anti-cancer immunotherapies predominantly target tumor-associated antigens, which are also present in normal tissues.
  • The potential of tumor-specific antigens as ideal targets for immunotherapy remains largely untapped.

Conclusions:

  • Despite their ideal properties, tumor-specific antigens are underutilized in current cancer immunotherapy.
  • Further research into novel tumor-specific epitopes and approaches is needed to improve immunotherapy success.
  • Targeting tumor-specific antigens holds significant promise for advancing cancer treatment, especially for solid tumors.